Jamie Brett discusses the similarities and differences between ESR1 mutations and fusions and why they are grouped together.
Jamie Brett
Advertisement
Articles by Jamie Brett
Jamie Brett, resident in internal medicine at Massachusetts General Hospital, discusses the effectiveness of CDK4/6 for patients with hormone receptor-positive metastatic breast cancer (MBC) with ESR1 mutations and fusions.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
